The positive Phase I data evaluating a new oral formulation of ezutromid for Duchenne Musclar Dystrophy (DMD) is extremely encouraging and supports the potential development of an improved formulation. The new formulation will now be incorporated into the ongoing PhaseOut DMD trial with the initial muscle biopsy data now expected Q2/Q3 2017 (from Q1). We are currently forecasting c.$2bn of ezutromid peak sales, supported by the broad utility of the programme across all patients with DMD and in c ....
